MYO18A and central nervous system cancer: Also, a positive correlation was demonstrated between tumor volume and <i>MYO18A</i> expression.<h4>Conclusion</h4>The level of expression of <i>MYO18A</i> can be considered a prognostic factor for PFS in patients treated for G4 gliomas, because higher <i>MYO18A</i> expression was associated with earlier recurrence.